News brief­ing: Sanofi ponies up more mon­ey to ex­pand pro­tein degra­da­tion col­lab with Nurix; Bio­gen fires shot at No­var­tis in new Spin­raza tri­al

Sanofi has agreed to shell out an ad­di­tion­al $22 mil­lion — bring­ing its to­tal cash in­vest­ment to $77 mil­lion — to ex­pand a dis­cov­ery pact with Nurix Ther­a­peu­tics for up to five tar­get­ed pro­tein degra­da­tion can­di­dates, the com­pa­nies said Thurs­day.

The phar­ma gi­ant and small biotech orig­i­nal­ly tied up in De­cem­ber 2019, agree­ing to pur­sue three of Nurix’s can­di­dates, which use E3 lig­as­es to se­lec­tive­ly tar­get pro­tein re­cep­tor sites. That deal came with up to $2.5 bil­lion in fu­ture mile­stones — a fig­ure that stayed the same with Sanofi’s ex­pan­sion of the deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.